The Synthesis Company of San Francisco Mountain Logo
Olgotrelvir as a Standalone Treatment for Nonhospitalized COVID-19 Patients (MPR-COV-301CN): A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial | doi.page